Loading company…
Munich-based pharmaceutical company developing targeted therapies aimed at improving patient outcomes in oncology.
Priaxon AG develops pharmaceuticals and proprietary compounds for targeted therapies, primarily in oncology, with the aim of inhibiting tumor growth and improving existing cancer treatments. Founded in Munich, Germany, the company is at the Seed stage and has completed one deal. Its funding came from Inveni Capital in May 2008.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in